The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.
Study Type
OBSERVATIONAL
Enrollment
412
Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
Percentage of patients achieving Psoriasis Area Severity Index 75% response at observational point 2
The Psoriasis Area Severity Index (PASI75) response assessments are based on at least 75 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked).
Time frame: From Baseline up to Week 21
Change from Baseline in Dermatology Life Quality Index score at observational point 2
The Dermatology Life Quality Index (DLQI) consists of questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI score ranges from 0 to 30 with higher scores indicating lower health-related quality of life (HRQoL).
Time frame: From Baseline up to Week 21
Change from Baseline in Dermatology Life Quality Index score at observational point 4
The Dermatology Life Quality Index (DLQI) consists of questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI score ranges from 0 to 30 with higher scores indicating lower health-related quality of life (HRQoL).
Time frame: From Baseline up to Week 56
Percentage of patients achieving Psoriasis Area Severity Index 75% response at observational point 4
The Psoriasis Area Severity Index (PASI75) response assessments are based on at least 75 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked).
Time frame: From Baseline up to Week 56
Percentage of patients achieving Psoriasis Area Severity Index 90% response at observational point 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ps0026 101
Brussels, Belgium
Ps0026 103
Brussels, Belgium
Ps0026 107
Brussels, Belgium
Ps0026 102
Leuven, Belgium
Ps0026 110
Maldegem, Belgium
Ps0026 109
Mons, Belgium
Ps0026 104
Namur, Belgium
Ps0026 208
London, Canada
Ps0026 209
London, Canada
Ps0026 201
Markham, Canada
...and 69 more locations
The Psoriasis Area Severity Index (PASI90) response assessments are based on at least 90 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked).
Time frame: From Baseline up to Week 21
Percentage of patients achieving Psoriasis Area Severity Index 90% response at observational point 4
The Psoriasis Area Severity Index (PASI90) response assessments are based on at least 90 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked).
Time frame: From Baseline up to Week 56